Use of Antiretroviral Drugs to Prevent HIV-1 Transmission Through Breast-feeding: From Animal Studies to Randomized Clinical Trials

Journal of Acquired Immune Deficiency Syndromes

Volumn 35, Issue 2, 2004, Pages 178-187

  Gaillard, Philippe ^a   Fowler, Mary Glenn ^b   Dabis, Francois ^c   Coovadia, Hoosen ^d   Van Der Horst, Charles ^e   Van Rompay, Koen ^f   Ruff, Andrea ^g   Taha, Taha ^g   Thomas, Tim ^h   De Vincenzi, Isabelle ^a   Newell, Marie Louise ⁱ  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c INSERM   (France)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^h KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiretroviral drugs; Prevention; Transmission through breastfeeding

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; TENOFOVIR; ZIDOVUDINE;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST FEEDING; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INOCULATION; MACACA; NEUTROPENIA; NEWBORN CARE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SHORT COURSE THERAPY; VIRUS LOAD; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BREAST FEEDING; DISEASE MODELS, ANIMAL; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV-1; HUMANS; MILK; MILK, HUMAN; RANDOMIZED CONTROLLED TRIALS;

EID: 9144253114     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200402010-00013     Document Type: Review

References (39)

1. Dorenbaum A, Cunningham CK, Gellber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission. JAMA. 2002;288:189-198.
2. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-494.
3. De Cock KM, Fowler MG, Mercicr E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000;283:1175-1182.
4. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 month follow-up to the HIVNET012 randomized trial. Lancet. 2003;362:59-68.
5. Leroy V, Karon JM, Alioum A, et al. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. AIDS. 2002;16:631-641.
6. The Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double blind, placebo-controlled study. Lancet. 2002;359: 1178-1186.
7. Van Rompay KKA, Otsyula MG, Martas ML, et al. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother. 1995:39:125-131.
8. Van Rompay KKA, Marthas ML, Ramos RA, et al. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3′-azido-3′ -deoxythymidine prevents SIV infection. Antimicrob Agents Chemother. 1992;36: 2381-2386.
9. Van Rompay KKA, Berardi CJ, Aguirre NL, et al. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS. 1998;12:F79-F83.
10. Van Rompay KKA, McChesney NL, Aguirre KA, et al. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis. 2001;184:429-438.
11. Van Rompay KKA, Miller DM, Marthas ML, et al. Prophylactic and therapeutic benefits of short-term 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol. 2000;74:1767-1774.
12. Connor EM, Sperling RS, Gelber RS, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
13. Guay L, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795-802.
14. Moodley D, Moodley J, Coovadia H, et al. A multicentre randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to refuse intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003; 187:725-735.
15. Miotti PG, Taha TE, Kumwenda NI, et al. HIV transmission from breastfeeding: a study in Malawi. JAMA. 1999;282:744-749.
16. Read JS, Newell M-L, Leroy V, et al. Late postnatal transmission of HIV in breastfed children: an individual patient data meta-analyses (The Breastfeeding and HIV International Transmission Study). Paper presented at: Tenth Conference on Retroviruses and Opportunistic Infections: February 10-14, 2003: Boston. Abstract 97.
17. Leroy V, Newell ML, Dabis F, et al. International multicentre pooled analyses of late postnatal mother-to-child transmission of HIV-1 infection. Lancet. 1998;352:597-600.
18. Nduati R, John GC, Mbori-Ngacha D, et al. Effect of breast-feeding and formula feeding on Transmission of HIV-1: a randomized clinical trial. JAMA. 2000;283:1167-1174.
19. Taba TE, Kumwenda N, Gibbons A, et al. Short postexposure prophylaxis in newborn infants in reduce mother-to-child transmission of HIV-1: NVAZ randomized clinical trial. Lancet. 2003;362:1171-1177.
20. Gray G, Urban M, Violoar A, et al. Preliminary analysis of a randomised controlled study to assess the role of post-exposure prophylaxis in reducing mother to child transmission of HIV-1. Paper presented at: XIV International AIDS Conference: July 7-12, 2002: Barcelona. LB0R13
21. Dabis F, Ekouevi DK, Bequel K, et al. A short course of zidovudine + peripartum nevirapine is highly efficacious in preventing mother-in-child transmission of HIV-1: the ANRS 1201 DITRAME-plus Study, Abidjan, Côte d'lvoire. Paper presented at; 10th Conference on Retroviruses and Opportunistic Infections: February 10-14, 2003; Boston. Abstract 854.
22. Shetty A, Coovadia HM, Maldonado Y, et al. HIVNET 023: a phase II/III study of the safety and plasma concentrations of nevirapine given daily, twice a week or weekly as HIV prophylaxis in breastfeeding infants from birth to 24 weeks in Durban, South Africa and Harare, Zimbabwe. Paper presented at: 3rd Conference on the Global Strategies for the Prevention of HIV Transmission from Mothers in Infants: September 9-13, 2001; Kampala, Uganda. Abstract 123.
23. Semba RD, Kumwenda N, Hoover DR, et al. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 1999;180:93-98.
24. Pillay K, Coutsoudis A, York D, et al. Cell-free virus in breast milk of HIV-1 seropositive women. J Acquir Immune Defic Syndr. 2000;24:330-336.
25. Ioannidis JP, Abrams EJ, Amman A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis. 2001;183:539-545.
26. WHO (2002). Sealing up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Available at: http://www. who.int/hiv/pub/sti/pub6/en/accessed March 3, 2003.
27. Mofenson LM, Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV for HIV-infected pregnant women and their infants. J Acquir Immune Defic Syndr. 2002;30:200-215.
28. Culnane M, Fowler MG, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA. 1999;281:151-157.
29. Hanson IC, Antonelli TA, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:463-467.
30. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:380-387.
31. Public Health Service Task Force. Recommendations for the use of antiretroviral drugs in [regnant HIV-1 infectd women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Recomm Rep. 2002;51(RR-181):1-38
32. Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep. 2001; 49:1153-1156.
33. Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministerd with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis. 1998;178:1327-1333.
34. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neconates (HIVNET 006). AIDS. 1999;13:479-486.
35. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok. Thailand: a randomised controlled trial. Lancet. 1999;353:773-780.
36. Sperling RS, Shapiro DE, McSherry GD, et al. Safety of the maternal-infant zidovudine regimen used in the Pediatric AIDS Clinic Trials Group 076 study. AIDS. 1998;12:1805-1813.
37. Mandelbrot L, Landreau-Mascaro A, Rekucewica C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA. 2001;285:2083-2093.
38. Blanche S, Tardicu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084-1089.
39. Perinatal Safety Review Working Group. Nuclcoside exposure in the offspring of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in 5 U.S. cohorts. J Aquir Immune Defic Syndr Hum Retrovirol. 2000;25:261-268.